文献速递浆细胞疾病

靶向浆细胞内质网蛋白稳态以减少致淀粉样轻链分泌

Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion.
PubMed 文献 · Blood Adv · 2021-01-01

该研究探讨化合物147对AL患者浆细胞分泌致淀粉样轻链的影响。化合物147通过共价修饰PDI等内质网蛋白稳态因子减少轻链分泌,且不依赖ATF6激活,也不干扰硼替佐米对浆细胞的毒性,提示可与化疗联用。

要点

  • 化合物147减少AL患者浆细胞分泌致淀粉样轻链。
  • 该作用不依赖ATF6激活,而依赖PDI等因子的共价修饰。
  • 化合物147不干扰硼替佐米对AL浆细胞的毒性。

核心结论

  • 化合物147通过选择性共价修饰内质网蛋白稳态因子减少致淀粉样轻链分泌,可与化疗联用降低AL致病相关轻链毒性。

研究设计与样本

  • 研究使用AL患者来源的浆细胞,评估化合物147对致淀粉样轻链分泌的影响及机制。

主要发现

  • 化合物147减少AL患者浆细胞分泌聚集倾向的单体和二聚体形式致淀粉样轻链。
  • 化合物147依赖共价修饰PDI等内质网蛋白稳态因子减少轻链分泌,不依赖ATF6激活。
  • 化合物147不干扰硼替佐米诱导的AL浆细胞毒性。

临床怎么用

  • 化合物147代表的靶向内质网蛋白稳态策略可与化疗联用,减少AL中轻链毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Light chain (LC) amyloidosis (AL) involves the toxic aggregation of amyloidogenic immunoglobulin LCs secreted from a clonal expansion of diseased plasma cells. Current AL treatments use chemotherapeutics to ablate the AL plasma cell population. However, no treatments are available that directly reduce the toxic LC aggregation involved in AL pathogenesis. An attractive strategy to reduce toxic LC aggregation in AL involves enhancing endoplasmic reticulum (ER) proteostasis in plasma cells to reduce the secretion and subsequent aggregation of amyloidogenic LCs. Here, we show that the ER proteostasis regulator compound 147 reduces secretion of an amyloidogenic LC as aggregation-prone monomers and dimers in AL patient-derived plasma cells. Compound 147 was established to promote ER proteostasis remodeling by activating the ATF6 unfolded protein response signaling pathway through a mechanism involving covalent modification of ER protein disulfide isomerases (PDIs). However, we show that 147-dependent reductions in amyloidogenic LCs are independent of ATF6 activation. Instead, 147 reduces amyloidogenic LC secretion through the selective, on-target covalent modification of ER proteostasis factors, including PDIs, revealing an alternative mechanism by which this compound can influence ER proteostasis of amyloidogenic proteins. Importantly, compound 147 does not interfere with AL plasma cell toxicity induced by bortezomib, a standard chemotherapeutic used to ablate the underlying diseased plasma cells in AL. This shows that pharmacologic targeting of ER proteostasis through selective covalent modification of ER proteostasis factors is a strategy that can be used in combination with chemotherapeutics to reduce the LC toxicity associated with AL pathogenesis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rius B, Mesgarzadeh JS, Romine IC, et al. Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Adv. 2021. PMID: 33599742. doi:10.1182/bloodadvances.2020002813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。